PHASE 2 STUDY OF ORAL DECITABINE AND CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)

被引：0
|
作者：
Zeidan, A. [1 ]
Mosher, K. [2 ]
Souza, S. [2 ]
Mirakhur, B. [2 ]
Taylor, J. [2 ]
Keer, H. [2 ]
机构：
[1] Yale Canc Ctr, Hematol, New Haven, CT USA
[2] Astex Pharmaceut Inc, Clin Dev, Pleasanton, CA USA
来源：
LEUKEMIA RESEARCH | 2023年 / 128卷
关键词：
D O I：
10.1016/j.leukres.2023.107273
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P138
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase 2 Study of Oral Decitabine/Cedazuridine in Combination with Magrolimab for Previously Untreated Subjects with Intermediate to Very High-Risk Myelodysplastic Syndromes (MDS)
    Zeidan, Amer M.
    Mosher, Karen
    Souza, Sonia
    Mirakhur, Beloo
    Keer, Harold N.
    Taylor, Jason A.
    BLOOD, 2022, 140 : 9779 - 9780
  • [2] A Phase 2 Dose-Confirmation Study of Oral ASTX727, a Combination of Oral Decitabine with a Cytidine Deaminase Inhibitor (CDAi) Cedazuridine (E7727), in Subjects with Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Griffiths, Elizabeth A.
    Roboz, Gail J.
    Busque, Lambert
    Wells, Richard A.
    Odenike, Olatoyosi
    Steensma, David P.
    Yee, Karen W. L.
    Faderl, Stefan
    Amrein, Philip C.
    Michaelis, Laura C.
    Kantarjian, Hagop M.
    Oganesian, Aram
    Lowder, James N.
    Azab, Mohammad
    Savona, Michael R.
    BLOOD, 2017, 130
  • [3] A Phase 1 Study to Assess the Absolute Bioavailability and Safety of An Oral Solution of Decitabine In Subjects with Myelodysplastic Syndromes (MDS)
    Mistry, Bipin
    Jones, Mark M.
    Kubiak, Peter
    Garcia-Manero, Guillermo
    Litzow, Mark R.
    Mesa, Ruben A.
    Rifkin, Robert
    Tarassoff, Peter
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 1624 - 1624
  • [4] Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes (MDS).
    Kim, E.
    Pan, F.
    Peng, S.
    Fleurence, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment-Naive High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
    Venugopal, Sangeetha
    Kantarjian, Hagop
    Maiti, Abhishek
    Short, Nicholas J.
    Montalban-Bravo, Guillermo
    Alvarado, Yesid
    Chien, Kelly S.
    Kanagal-Shamanna, Rashmi
    Pemmaraju, Naveen
    Davel, Naval
    Kadia, Tapan M.
    Borthakur, Gautam
    Jabbour, Elias J.
    Garcia-Manero, Guillermo
    BLOOD, 2021, 138
  • [6] Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS
    Rao, Arati
    Khan, Ghazi
    Rizzieri, David A.
    Moore, Joseph O.
    Gockerman, Jon P.
    Diehl, Louis F.
    Beaven, Anne W.
    Adams, Donna
    Warzecho, Julie
    Decastro, Carlos
    BLOOD, 2012, 120 (21)
  • [7] A Phase I/II Study of Venetoclax in Combination With ASTX727 (Decitabine/Cedazuridine) in Treatment-Naive High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
    Venugopal, Sangeetha
    Kantarjian, Hagop
    Maiti, Abhishek
    Short, Nicholas J.
    Montalban-Bravo, Guillermo
    Alvarado, Yesid
    Chien, Kelly
    Kanagal-Shamanna, Rashma
    Pemmaraju, Naveen
    Daver, Naval
    Kadia, Tapan
    Borthakur, Gautam
    Jabbour, Elias
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S321 - S321
  • [8] Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study
    Garcia-Manero, Guillermo
    Griffiths, Elizabeth A.
    Steensma, David P.
    Roboz, Gail J.
    Wells, Richard
    McCloskey, James, II
    Odenike, Olatoyosi
    DeZern, Amy E.
    Yee, Karen
    Busque, Lambert
    O'Connell, Casey
    Michaelis, Laura C.
    Brandwein, Joseph
    Kantarjian, Hagop
    Oganesian, Aram
    Azab, Mohammad
    Savona, Michael R.
    BLOOD, 2020, 136 (06) : 674 - 683
  • [9] Phase 2 Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome- Outcome in Previously Untreated Patients.
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Konopleva, Marina
    Burger, Jan A.
    Thomas, Deborah A.
    Kadia, Tapan
    Williams, Betsy
    George, Sully
    Kantarjian, Hagop
    BLOOD, 2009, 114 (22) : 435 - 436
  • [10] Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results
    Sallman, David
    Al Malki, Monzr
    Asch, Adam
    Wang, Eunice
    Jurcic, Joseph
    Bradley, Terrence
    Flinn, Ian
    Pollyea, Daniel
    Kambhampati, Suman
    Tanaka, Tiffany
    Zeidner, Joshua
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Gu, Lin
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol
    Lal, Indu
    Vyas, Paresh
    Daver, Naval
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S314 - S315
12345